FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period

Bayer

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Darifenacin (Emselex, BAY79-4998)

Study type: Observational

Funder types: Industry

Identifiers

NCT00921245

EX0710ZA (Other Identifier)

13027

Details and patient eligibility

About

Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients > 18 years with symptoms of overactive bladder.

Exclusion criteria

• Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert.
• Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception.
• Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.

Trial design

9 participants in 1 patient group

Group 1

Treatment:

Drug: Darifenacin (Emselex, BAY79-4998)